• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Nephrology

Nivolumab and cabozantinib superior to sunitinib for advanced renal-cell carcinoma

bySze Wah Samuel ChanandHarsh Shah
March 10, 2021
in Nephrology, Oncology
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. The combination of nivolumab and cabozantinib was superior to sunitinib in untreated advanced renal-cell carcinoma

2. The combination treatment caused more drug discontinuation compared to sunitinib.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In advanced renal-cell carcinoma, sunitinib is the standard of care, but the landscape of different regimens is evolving. Previous trials of single-agent cabozantinib, a tyrosine kinase inhibitor (TKI), and nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor, have been effective as the first-line treatment. This trial compared the combination of nivolumab and cabozantinib to sunitinib. The combination treatment improved overall survival, progression-free survival, and higher objective response rates. Additionally, grade 3 or above adverse events and study drug discontinuation occurred more often in the combination group. Quality of life was better maintained in the combination group compared to the sunitinib group. Study limitations included median overall survival was not reached in both groups. Overall, this trial showed the superiority of the combination treatment in advanced renal-cell carcinoma.

Click here to read the study in the NEJM (New England Journal of Medicine)

Relevant Reading: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

RELATED REPORTS

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

In-Depth [randomized controlled trial]: This phase 3, randomized, open-label clinical trial enrolled 651 patients at 125 sites in 18 countries. Patients diagnosed with untreated advanced renal cell carcinoma with a clear cell component and who received no previous systemic therapies were included in the study. Patients with active central nervous system metastases or active autoimmune disease were excluded from the study. Patients were randomized in a 1:1 ratio to either nivolumab and cabozantinib or sunitinib, respectively. The median follow-up was 18.1 months. The combination group had superior overall survival (hazard ratio [HR], 0.6; 95% confidence interval [CI], 0.40 to 0.89), progression-free survival (HR, 0.51; 95% CI, 0.41 to 0.64), and objective response (combination group, 55.7%; sunitinib group, 27.1%; P < 0.001). FKSI-19 (Functional Assessment of Cancer Therapy-Kidney Symptom Index), a measure of the quality of life, was higher in the combination group (P < 0.05). Grade 3 or above adverse events occurred in 75.3% of patients in the combination group and 70.6% of the sunitinib group. Finally, 19.7% of patients in the PD-L1/TKI group discontinued a study medication and 16.9% stopped the treatment in the sunitinib group. Overall, the combination regiment is a viable option as first-line treatment for carefully selected patients.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cabozantinibNivolumabrenal-cell carcinomasunitinib
Previous Post

#VisualAbstract: Tocilizumab reduced COVID-19 disease related adverse health outcomes

Next Post

Different gestational diabetes screening methods cause no difference for complications

RelatedReports

Liver cancer immunotherapy collage: an engraved liver and gallbladder with round immune cells at its edge and a potted fern
Chronic Disease

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

August 27, 2025
Colorectal cancer collage: an engraved large intestine beside a blue awareness ribbon, a water bottle and a folded towel
Chronic Disease

Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

April 3, 2025
Neuroendocrine tumor treatment collage: a calm freckled woman beside a wooden hourglass and a round white tablet
Endocrinology

Cabozantinib significantly improves progression free survival in patients with advanced neuroendocrine tumors

August 29, 2026
Radiographic surrogates may predict tumor-specific survival in renal carcinoma
Pharma

Bristol Myers Squibb: Opdivo-Qvantig is the first FDA approved subcutaneous version of cancer immunotherapy targeting PD-1

February 17, 2025
Next Post

Different gestational diabetes screening methods cause no difference for complications

Whole-genome sequencing more accurate than cytogenetic analysis in myeloid cancers

Combined division of the splenic vein a safe method for distal pancreatectomy

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • AI Model Shows Promise in Predicting PTSD Risk Following Trauma
  • 2 Minute Medicine Rewind November 16, 2026
  • ERX1000 plus semaglutide increased weight loss and metabolic measures in diet-induced obese mice
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.